[1. Blachier M, Leleu H, Peck-Radosavljevic M. The burden of liver disease in Europe: A review of available epidemiological data. J Hepatology, 58, 2013, № 3, 593-608.10.1016/j.jhep.2012.12.00523419824]Search in Google Scholar
[2. Elpek G. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. World J Gastroenterol, 20, 2014, № 23, 7260-7276.10.3748/wjg.v20.i23.7260406407224966597]Search in Google Scholar
[3. Göbel T, Erhardt A, Herwig M, et al. High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in central Europe. J Med Virol, 83, 2011, № 6, 968-973.10.1002/jmv.2204821503908]Search in Google Scholar
[4. Hernandez-Gea V, Scott L. Friedman SL. Pathogenesis of Liver Fibrosis: mechanisms of disease. Ann Rev Pathol, 6, 2011, № 2, 425-456.10.1146/annurev-pathol-011110-13024621073339]Search in Google Scholar
[5. Iredale JP, Thompson A, Henderson NC. Extracellular matrix degradation in liver fibrosis. Biochim Biophys Acta (BBA), 1832, 2013, № 7, 876-883.10.1016/j.bbadis.2012.11.00223149387]Search in Google Scholar
[6. Gordon SC, Lamerato LE, Rupp LB et al. Prevalence of Cirrhosis in Hepatitis C Patients in the Chronic Hepatitis Cohort Study (CHeCS): A Retrospective and Prospective Observational Study. Am J Gastroent, 110, 2015, № 8, 1169-1177.10.1038/ajg.2015.203573124226215529]Search in Google Scholar
[7. Rossi E, Adams LA, Bulsara M et al. Assessing Liver Fibrosis with Serum Marker Models. Clin Biochem Rev, 28, 2007, № 1, 3-10.]Search in Google Scholar
[8. Baranova A, P. La P, A. Birerdinc. Non-invasive markers for hepatic fibrosis. BMC Gastroenterology, 11, 2011, № 1, 91-98.10.1186/1471-230X-11-91317618921849046]Search in Google Scholar
[9. Fallatah HI. Noninvasive Biomarkers of Liver Fibrosis: An Overview. Adv Hepat, 2014, 2014, Article ID 357287, 15.10.1155/2014/357287]Search in Google Scholar
[10. Lombardi R, Buzzetti E, Roccarina D, and Emmanuel A. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. World J Gastroenterol, 21, 2015, № 39, 11044-11052.10.3748/wjg.v21.i39.11044460790426494961]Search in Google Scholar
[11. Gordon SC, Lamerato LE, Rupp LB et al. Prevalence of Cirrhosis in Hepatitis C Patients in the Chronic Hepatitis Cohort Study (CHeCS): A Retrospective and Prospective Observational Study. Am J Gastroent, 110, 2015, № 8, 1169-1177.10.1038/ajg.2015.203]Search in Google Scholar
[12. Gressner, CF Gao, Gressner OA. Non-invasive biomarkers for monitoring the fibrogenicprocess in liver: A short survey. World J Gastroenterol, 15, 2009, № 20, 2433-2440.10.3748/wjg.15.2433268689819468990]Search in Google Scholar
[13. Mayeux R. Biomarkers: Potential Uses and Limitations. NeuroRx, 1, 2004, № 2, 182-188. doi:10.1602/neurorx.1.2.182.10.1602/neurorx.1.2.18253492315717018]Search in Google Scholar
[14. Huang H, Wu T Mao J, et al. CHI3L1 Is a Liver-Enriched, Noninvasive Biomarker That Can Be Used to Stage and Diagnose Substantial Hepatic Fibrosis. J Integrat Biol, 19, 2015, № 6, 339-345.10.1089/omi.2015.0037448671326415140]Search in Google Scholar
[15. Papastergiou V, Tsochatzis E, Andrew K. Non-invasive assessment of liver fibrosis Ann Gastroenterol, 25, 2012, № 3, 218-231.]Search in Google Scholar
[16. Cox-North PP, Shuhart MC Core Concepts. Evaluation and Staging of Liver Fibrosis. Last Updated: October 22nd, 2015.]Search in Google Scholar
[17. Lurie Y, Webb M, Cytter-Kuint R, et al. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol, 21, 2015, № 41, 11567-11583.10.3748/wjg.v21.i41.11567463196126556987]Search in Google Scholar
[18. Liu T, Wang X, Karsdal MA, et al. Molecular Serum Markers of Liver Fibrosis. Biomark Insights, 7, 2012, № 1, 105-117.10.4137/BMI.S10009341261922872786]Search in Google Scholar
[19. Tsochatzis EA, Crossan C Longworth L. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. Hepatology, 60, 2014, № 3, 832-843.10.1002/hep.27296426529525043847]Search in Google Scholar
[20. Zhang D, Wang NY, Yang CB, et al. The clinical value of serum connective tissue growth factor in the assessment of liver fibrosis. Dig Dis Sci, 55, 2010, № 3, 767-74.10.1007/s10620-009-0781-919294506]Search in Google Scholar
[21. Leroy V, Monier M, Bottari S, et al. Circulating Matrix Metalloproteinases 1, 2, 9 and Their Inhibitors TIMP-1 and TIMP-2 as Serum Markers of Liver Fibrosis in Patients With Chronic Hepatitis C: Comparison With PIIINP and Hyaluronic Acid Metalloproteinases and Their Inhibitors as Serum Markers. Am J Gastroent, 99, 2004, № 2, 271-279.10.1111/j.1572-0241.2004.04055.x15046217]Search in Google Scholar
[22. De Lucca Schiavon L, Narciso-Schiavon J, de Carvalho-Filho R et al. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol. 20, 2014, № 11, 2854-2866.10.3748/wjg.v20.i11.2854396199224659877]Search in Google Scholar
[23. Haukeland JW, Lorgen I, Schreiner LT, et al. AST/ALT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis. Scand J Gastroenterol, 43, 2008, № 10, 1241-1248.10.1080/0036552080215861418609128]Search in Google Scholar
[24. Lin ZH, Xin YN, Dong QJ et al. Performance of the aspar-tate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology, 53, 2011, № 3, 726-736.10.1002/hep.24105]Search in Google Scholar
[25. Wenwen J, Zhonghua L, Yongning X, et al. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis. Gastroenterol, 12, 2012, № 1, 14. Published online 2012 Feb 14. doi: 10.1186/1471-230X-12-1410.1186/1471-230X-12-14]Search in Google Scholar
[26. Zaman A, Rosen HR, Ingram K et al. Assessment of FIBRO Spect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med, 120, 2007, № 3, 280-291.10.1016/j.amjmed.2006.06.044]Search in Google Scholar
[27. Salkic NN, Jovanovic P, Hauser G, et al. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Am J Gastroenterol, 109, 2014, № 6, 796-806.10.1038/ajg.2014.21]Search in Google Scholar
[28. Lichtinghagen R, Pietsch D, Bantel H, et al. The Enhanced Liver Fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values. J Hepatology, 59, 2013, № 2, 236-242.10.1016/j.jhep.2013.03.016]Search in Google Scholar
[29. Parkes J, Guha IN, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology, 47, 2008, № 2, 455-460.10.1002/hep.21984]Search in Google Scholar
[30. Guechot J, Trocme C, Renversez JC et al. Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C. Clin Chem Lab Med. 50, 2012, № 4, 693-699.10.1515/cclm-2011-0858]Search in Google Scholar
[31. Trembling PM, Lampertico P, Parkes J. Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. J Viral Hepat, 21, 2014, № 6, 430-438.10.1111/jvh.12161]Search in Google Scholar
[32. Boeker KH, Haberkorn CI, Michels D. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta, 316, 2002, № 1-2, 71-81.10.1016/S0009-8981(01)00730-6]Search in Google Scholar